Government jobs • Exam updates • PreparationIndependent information portal
RojgarRankYOUR NEXT STEP STARTS HERE
Current Affairs

Teplizumab: The First Immunotherapy Drug to Delay Onset of Type 1 Diabetes Approved on NHS

By Published

Teplizumab, marketed as Tzield, is the first immunotherapy approved to delay the progression from stage 2 to stage 3 type 1 diabetes. It is licensed in the UK for patients aged 8 years and above and has received NHS approval in England and Wales as of June 2026. Administered via a 14-day intravenous infusion course, it temporarily preserves insulin-producing beta cells, delaying the need for insulin therapy by approximately 2 to 3 years.

On this page

Key Facts

  • Teplizumab (brand name Tzield) is the first immunotherapy drug designed to delay the onset of symptomatic (stage 3) type 1 diabetes.
  • It received licensing from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in August 2025 and NHS approval by NICE in June 2026 for use in England and Wales.
  • Indicated for individuals aged 8 years and older who are at stage 2 of type 1 diabetes — characterized by the presence of multiple autoantibodies and dysglycemia, but not yet requiring insulin therapy.
  • The treatment consists of a one-time 14-day course of daily intravenous infusions, each lasting about 30 minutes.
  • Clinical trials demonstrated that teplizumab delays progression to stage 3 (clinical diabetes requiring insulin) by an average of about three years.
  • Approximately 1,100 eligible patients are expected to access treatment in the first year, with around 820 treated annually thereafter on the NHS in England and Wales.
  • Teplizumab is manufactured by Sanofi.

Background & Context

Type 1 diabetes (T1D) is an autoimmune disease where the body's immune system attacks pancreatic beta cells that produce insulin. T1D progression is classified into three clinical stages:

  • Stage 1: Presence of multiple islet autoantibodies, normal blood glucose levels, asymptomatic.
  • Stage 2: Multiple autoantibodies present with dysglycemia (abnormal glucose tolerance) but no clinical symptoms or insulin need.
  • Stage 3: Onset of symptomatic diabetes meeting clinical diagnostic criteria requiring insulin therapy.

Teplizumab functions by modulating the immune system, specifically targeting CD3+ T cells, to slow the autoimmune destruction of beta cells during stage 2, thus postponing clinical onset.

Why This Matters for Exams / Exam Relevance

  • It represents the first disease-modifying therapy available in the UK that targets the root cause rather than symptoms of type 1 diabetes.
  • Understanding T1D stages (1, 2, and 3) and the timing of therapeutic intervention is critical.
  • Knowledge of NICE and MHRA’s roles in drug approval and NHS treatment adoption timelines is important.
  • Familiarity with treatment protocol: intravenous infusion over 14 days, patient eligibility, and expected clinical outcomes is essential.
  • Public health impact includes reducing burden of intensive insulin therapy and complications through disease delay.

Points to Remember

  • Stage 2 T1D: presence of autoantibodies and abnormal glucose without need for insulin—is the key eligibility stage.
  • Patients should be aged 8 years or more (current approved indication in the UK).
  • Administered once daily intravenously over 14 consecutive days in hospital.
  • MHRA licensing: August 2025; NICE final draft guidance: June 22, 2026.
  • NHS England expected to provide access within 90 days post-NICE guidance; NHS Wales within 60 days.
  • Screening for autoantibodies (e.g., via ELSA and T1DRA studies) enables early identification of candidates.
  • Teplizumab may also protect residual beta cells in newly diagnosed stage 3 patients; ongoing research may extend indications in future.
← Back to Current Affairs